HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Carlyle Trims Nature's Bounty Assets: Private Equity Rolls In Supplement Space

This article was originally published in The Rose Sheet

Executive Summary

Carlyle's $2.2bn sale of Nature's Bounty's Holland & Barrett business to a Russian investment fund is the latest sign of the private equity sector's continuing interest in the health and wellness space.

You may also be interested in...

US FTC Collects First ‘Review Hijacking’ Bounty Against Nestle’s Bountiful Supplement Business

FTC proposes order to settle administrative complaint requiring Bountiful Company to pay $600,000 monetary relief for consumers. Order prohibits the Nestle business from using “variation” relationships in e-commerce ads, when positive reviews posted for one product may be confused with a different but similar product.

EU Business News: Reckitt Steps Up Sustainability, Merz Acquires Brooklyn Soap, Holland & Barrett Grows Footprint

Round-up of the latest European consumer health business news: Reckitt joins the RecyClass initiative to make its packaging more sutainable; Germany's Merz extends its Consumer Care offering with Brooklyn Soap acquisition; and retailer Holland & Barrett expands into Greece, Romania and Bulgaria.

KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride

Since acquiring Nature's Bounty in 2010 and taking the publicly traded firm private, Carlyle could have been at the helm longer than executives at the private equity firm intended or expected, exceeding the five-year plan typical for similar investments.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts